Triacetyldiphenolisatin
Triacetyldiphenolisatin is a triacetate prodrug of diphenolisatin, a stimulant laxative that upon hydrolysis releases isatin compounds that stimulate colonic motility by irritating the colonic mucosa and increasing intestinal peristalsis. It was used for treatment of constipation but has largely been replaced by safer laxative agents. Its mechanism involves direct irritant stimulation of the colon similar to other anthraquinone-based laxatives.
Khối lượng phân tử
443,4000 g/mol
LogP
3,40
TPSA
90,00 Ų
Lipinski RO5
Đạt
Cơ chế tác dụng
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Cấu trúc 2D
Cite this structure
Embed this structure
SMILES
CC(=O)Oc1ccc(C2(c3ccc(OC(C)=O)cc3)C(=O)N(C(C)=O)c3ccccc32)cc1
InChI
InChI=1S/C26H21NO6/c1-16(28)27-24-7-5-4-6-23(24)26(25(27)31,19-8-12-21(13-9-19)32-17(2)29)20-10-14-22(15-11-20)33-18(3)30/h4-15H,1-3H3
Molecular Formula
C26H21NO6
HBD / HBA
- / 6
Liên kết có thể quay
6
Nguyên tử nặng
33
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Câu hỏi thường gặp
Triacetyldiphenolisatin is a triacetate prodrug of diphenolisatin, a stimulant laxative that upon hydrolysis releases isatin compounds that stimulate colonic motility by irritating the colonic mucosa and increasing intestinal peristalsis. It was used for treatment of constipation but has largely been replaced by safer laxative agents. Its mechanism involves direct irritant stimulation of the colon similar to other anthraquinone-based laxatives.
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Yes, Triacetyldiphenolisatin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1909288. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 29321. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="triacetyldiphenolisatin"></div>
Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/triacetyldiphenolisatin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>
Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/triacetyldiphenolisatin/
Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/triacetyldiphenolisatin/)
Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="triacetyldiphenolisatin"></drugfyi-drug>